11 August 2017 : Original article
Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation
Yutaka Hirano1ADEF, Seiichiro Sugimoto1ABCDEFG*, Toshifumi Mano1BCD, Takeshi Kurosaki2BCD, Kentaroh Miyoshi1ABC, Shinji Otani2ABC, Masaomi Yamane1ABC, Motomu Kobayashi3ABC, Shinichiro Miyoshi1ABC, Takahiro Oto2ABCDEFDOI: 10.12659/AOT.904225
Ann Transplant 2017; 22:484-492
Abstract
BACKGROUND: Although administration of tacrolimus, whether by the enteric, sublingual, or continuous intravenous routes, has some limitations, twice-daily bolus intravenous tacrolimus administration has been shown to be beneficial in optimizing efficacy and safety after lung transplantation. However, at present, the duration of bolus intravenous tacrolimus administration is limited, and the effects of prolonged bolus intravenous tacrolimus administration remain unknown. Our study was aimed at assessing the safety and efficacy of prolonged twice-daily bolus intravenous tacrolimus administration in the early phase after lung transplantation.
MATERIAL AND METHODS: We retrospectively investigated the data of 62 recipients of lung transplantation who had received twice-daily bolus intravenous administration of tacrolimus, followed by oral tacrolimus, after lung transplantation at our institution between January 2011 and October 2015.
RESULTS: The median duration of bolus intravenous tacrolimus administration was 19 days (4–72 days). The target trough level was achieved in 89% of the patients by day 3. Acute kidney injury occurred in 27% of the patients during bolus intravenous tacrolimus. Two patients (3%) had neurotoxicity, necessitating discontinuation of tacrolimus. Suspected acute rejection requiring steroid pulse therapy occurred in 21% of patients during the follow-up period. Eight patients (13%) developed chronic lung allograft dysfunction during the follow-up period. The 1-year and 5-year survival rates after lung transplantation were 95% and 76%, respectively.
CONCLUSIONS: These results suggest that prolonged bolus intravenous tacrolimus administration in the early phase after lung transplantation is a safe and effective alternative to enteric, sublingual, or continuous intravenous administration.
Keywords: Administration, Intravenous, Graft Rejection, Immunosuppression, Lung Transplantation, Tacrolimus
In Press
Original article
Effect of a Nursing Program on Anxiety, Depression, and Insomnia in Patients After Liver Transplantation: A...Ann Transplant In Press; DOI: 10.12659/AOT.947351
Original article
Family-Related Motivation and Regret Intensity Among Family Liver Donors by Type of Family RelationshipAnn Transplant In Press; DOI: 10.12659/AOT.947414
Most Viewed Current Articles
03 Jan 2023 : Original article 6,670
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
15 Aug 2023 : Review article 6,560
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
16 May 2023 : Original article 6,292
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
28 May 2024 : Original article 5,529
Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...DOI :10.12659/AOT.943281
Ann Transplant 2024; 29:e943281